- Photoconductive bent-core liquid crystalline radicals with a paramagnetic polar switchable phase
-
A series of self-organizing bent-core derivatives 1[12,n], containing a highly π-delocalized stable radical as the central angular structural element, is described. The planarity of the open-shell core permits efficient π-π stacking, which results in the formation of B2 and soft crystalline phases above 100 °C. Optical, XRD and dielectric analyses of 1[12,12] indicate that the ground state of the observed B2 phase is polar antiferroelectric of type SmCAPA exhibiting tristable electro-optical switching. SQUID and EPR measurements revealed strong antiferromagnetic spin-spin exchange interactions below the isotropic phase, which have been estimated at θ = -46 cm-1 with the Curie-Weiss law. Transient photoconductivity was observed in the B2 phase with a hole carrier mobility μh of 1.4 × 10-4 cm2 V-1 s-1
- Shivakumar, Kilingaru I.,Pociecha, Damian,Szczytko, Jacek,Kapu?ciński, Szymon,Monobe, Hirosato,Kaszyński, Piotr
-
supporting information
p. 1083 - 1088
(2020/02/05)
-
- Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors
-
Fe(II)/α-ketoglutarate-dependent lysine demethylases (KDMs) are attractive drug targets for several diseases including cancer. In this study, we designed and screened ortho-substituted anilides that are expected to function as Fe(II) chelators, and identified ortho-hydroxy anilide as a novel scaffold for KDM5A inhibitors. Treatment of human lung cancer A549 cells with a prodrug form of 4-carboxy-2-hydroxy-formanilide (9c) increased trimethylated lysine 4 on histone H3 level, suggesting KDM5 inhibition in the cells.
- Jaikhan, Pattaporn,Buranrat, Benjaporn,Itoh, Yukihiro,Chotitumnavee, Jiranan,Kurohara, Takashi,Suzuki, Takayoshi
-
supporting information
p. 1173 - 1176
(2019/03/29)
-
- Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors
-
We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.
- Shibuya, Kimiyuki,Kawamine, Katsumi,Miura, Toru,Ozaki, Chiyoka,Edano, Toshiyuki,Mizuno, Ken,Yoshinaka, Yasunobu,Tsunenari, Yoshihiko
-
p. 4001 - 4013
(2018/06/26)
-
- Synthesis of highly functionalized oligobenzamide proteomimetic foldamers by late stage introduction of sensitive groups
-
α-Helix proteomimetics represent an emerging class of ligands that can be used to inhibit an array of helix mediated protein-protein interactions. Within this class of inhibitor, aromatic oligobenzamide foldamers have been widely and successfully used. This manuscript describes alternative syntheses of these compounds that can be used to access mimetics that are challenging to synthesize using previously described methodologies, permitting access to compounds functionalized with multiple sensitive side chains and accelerated library assembly through late stage derivatisation.
- Burslem, George M.,Kyle, Hannah F.,Prabhakaran, Panchami,Breeze, Alexander L.,Edwards, Thomas A.,Warriner, Stuart L.,Nelson, Adam,Wilson, Andrew J.
-
p. 3782 - 3786
(2016/05/09)
-
- COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
-
The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical
- -
-
Paragraph 0329-0330
(2016/12/22)
-
- NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
-
The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
- -
-
Page/Page column 70
(2013/05/23)
-
- NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
-
The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
- -
-
Page/Page column 80
(2013/05/23)
-
- Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors
-
A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole- 6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers.
- Jonckers, Tim H.M.,Rouan, Marie-Claude,Hache, Geerwin,Schepens, Wim,Hallenberger, Sabine,Baumeister, Judith,Sasaki, Jennifer C.
-
supporting information; experimental part
p. 4998 - 5002
(2012/09/07)
-
- Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists
-
As a part of our program to develop OX1-CB1 bivalent ligands, we required a better understanding of the basic structure-activity relationships (SARs) of orexin antagonists. A series of SB-334867 analogues were synthesized and evaluated in calcium mobilization assays. SAR results suggest that the 2-methylbenzoxazole moiety may be replaced with a disubstituted 4-aminophenyl group without loss of activity and an electron-deficient system is generally preferred at the 1,5-naphthyridine moiety for OX1 antagonist activity. In particular, substitution of larger potential linkers such as n-hexyl provided compound 33 with equivalent activity at the OX1 receptor compared to the lead compound SB-334867. These compounds should be of value in the development of ligands targeting the orexin-1 receptor and its potential heterodimers.
- Perrey, David A.,Gilmour, Brian P.,Runyon, Scott P.,Thomas, Brian F.,Zhang, Yanan
-
scheme or table
p. 2980 - 2985
(2011/06/24)
-
- AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS
-
The present invention relates to compounds that have CYP450 inhibiting properties and are therefore useful as boosters of certain drugs, i.e. they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered. The invention further provides the use of said compounds as improvers of the bioavailability of certain drugs. Methods for the preparation of the compounds of the invention and pharmaceutical compositions are also provided.
- -
-
Page/Page column 21
(2010/12/29)
-
- Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4
-
The series of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-dione and 4-[(pyridylmethyl)aminometh-ylene]isoquinoline-1,3-(2H,4H)-dione derivatives reported here represents a novel class of potential antitumor agents, which potently and selectively inhibit CDK4 over CDK2 and CDK1. In the benzylamino headpiece, a 3-OH substituent is required on the phenyl ring for CDK4 inhibitory activity, which is further enhanced when an iodo, aryl, heteroaryl, t-butyl, or cyclopentyl substituent is introduced at the C-6 position of the isoquinoline-1,3-dione core. To circumvent the metabolic liability associated with the phenolic OH group on the 4-substituted 3-OH phenyl headpiece, we take two approaches: first, introduce a nitrogen o- or p- to the 3-OH group in the phenyl ring; second, replace the phenyl headpiece with N-substituted 2-pyridones. We present here the synthesis, SAR data, metabolic stability data, and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.
- Tsou,Liu, Xiaoxiang,Birnberg, Gary,Kaplan, Joshua,Otteng, Mercy,Tran, Tritin,Kutterer, Kristina,Tang, Zhilian,Suayan, Ron,Zask, Arie,Ravi, Malini,Bretz, Angela,Grillo, Mary,Mcginnis, John P.,Rabindran, Sridhar K.,Ayral-Kaloustian, Semiramis,Mansour, Tarek S.
-
scheme or table
p. 2289 - 2310
(2010/02/28)
-
- Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists
-
The structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. The 2-halogen analogues showed enhanced antagonism compared to the prototype antagonist.
- Lee, Jeewoo,Kang, Sang-Uk,Kil, Min-Jung,Shin, Myoungyoup,Lim, Ju-Ok,Choi, Hyun-Kyung,Jin, Mi-Kyoung,Kim, Su Yeon,Kim, Sung-Eun,Lee, Yong-Sil,Min, Kyung-Hoon,Kim, Young-Ho,Ha, Hee-Jin,Tran, Richard,Welter, Jacqueline D.,Wang, Yun,Szabo, Tamas,Pearce, Larry V.,Lundberg, Daniel J.,Toth, Attila,Pavlyukovets, Vladimir A.,Morgan, Matthew A.,Blumberg, Peter M.
-
p. 4136 - 4142
(2007/10/03)
-
- COMPOUNDS
-
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X is selected from (II) and (III), Y is selected from SO2NH, CONH, CH=N, CH2NH and CH=CH; R1-5 are each independently selected from H, OH, OR6, CO2H, C02R7, NO2, CN CONR8R9, CONHR10, CO2(CH2)nCO2R11, CO2(CH2)mO(CO)R12, CO2CHR13COR14, CONH(CH2)pCO2R15, CONH(CH2)qO(CO)R16, CONHCHRI7COR18; R6-18 are each independently hydrocarbyl; n, m, p and q are each independently 1, 2, 3 or 4; with the proviso that when X is phenyl, Y is CH=CH, R3 is OH and R1, R4 and R5 are H, R2 is other than COON. Further aspects of the invention relate to the use of such compounds in the preparation of a medicament for the treatment or prevention of transmissible spongiform encephalopathies (TSEs), and pharmaceutical compositions comprising the same.
- -
-
Page/Page column 15; 59-60
(2010/02/14)
-
- Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: Combining X-ray crystallography, 3D-QSAR, and tailored scoring functions
-
The design, synthesis, and structure-activity relationship of 3-oxybenzamides as potent inhibitors of the coagulation protease factor Xa are described on the basis of X-ray structures, privileged structure motifs, and SAR information. A total of six X-ray structures of fXa/inhibitor complexes led us to identify the major protein-ligand interactions. The binding mode is characterized by a lipophilic dichlorophenyl substituent interacting with Tyr228 in the protease S1 pocket, while polar parts are accommodated in S4. This alignment in combination with docking allowed derivation of 3D-QSAR models and tailored scoring functions to rationalize biological affinity and provide guidelines for optimization. The resulting models showed good correlation coefficients and predictions of external test sets. Furthermore, they correspond to binding site topologies in terms of steric, electrostatic, and hydrophobic complementarity. Two approaches to derive tailored scoring functions combining binding site and ligand information led to predictive models with acceptable predictions of the external set. Good correlations to experimental affinities were obtained for both AFMoC (adaptation of fields for molecular comparison) and the novel TScore function. The SAR information from 3D-QSAR and tailored scoring functions agrees with all experimental data and provides guidelines and reasonable activity estimations for novel fXa inhibitors.
- Matter, Hans,Will, David W.,Nazaré, Marc,Schreuder, Herman,Laux, Volker,Wehner, Volkmar
-
p. 3290 - 3312
(2007/10/03)
-
- Prenyl transferase inhibitors
-
A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R23); and the remaining substituents are as defined in the disclosure.
- -
-
-
- Synthesis of analogues of Congo red and evaluation of their anti-prion activity
-
No cure as of yet exists for any of the transmissible spongiform encephalopathies. In this paper, we describe the synthesis of analogues of Congo red and evaluation against a cellular model of infection, the SMB (scrapie mouse brain) persistently infected cell line, for their ability to inhibit the infectivity of the abnormal form of prion protein (PrP-res). The compounds have also been tested for their ability to inhibit the polymerization of PrP C by PrP-res. A number of analogues showed inhibition of PrP-res infectivity at nanomolar concentrations. Several analogues show promise; the most active compound, 2a, inhibits the formation of PrP-res in SMB cells with an EC50 of 25-50 nM.
- Sellarajah, Shane,Lekishvili, Tamuna,Bowring, Claire,Thompsett, Andrew R.,Rudyk, Helene,Birkett, Christopher R.,Brown, David R.,Gilbert, Ian H.
-
p. 5515 - 5534
(2007/10/03)
-
- Novel synthesis of benzoxazoles from o-nitrophenols and amines
-
o-Nitrophenols and o-nitroaniline were reacted with amines at 210-215°C to produce the corresponding benzoxazoles and benzimidazoles, respectively, in moderate yields. The reactions between o-nitrophenols containing a CO2Me or OMe group on their benzene rings and N,N-diethylaniline were examined to investigate the effects of the position and electronic character of these substituents on the formation of the oxazole ring.
- Nishioka, Hiromi,Ohmori, Yukiko,Iba, Yumiko,Tsuda, Eri,Harayama, Takashi
-
p. 193 - 198
(2007/10/03)
-
- Method of treating cancer
-
The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
- -
-
-
- INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
-
The present invention is directed to compounds which inhibit prenyl-protein transferases, farnesyl-protein transferase and geranylgeranyl-protein transferase type I, and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I and the prenylation of the oncogene protein RAS.
- -
-
-
- Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I
-
Compound 1 has been shown to be a dual prenylation inhibitor with FPTase (IC50=2 nM) and GGPTase-I (IC50=95 nM). Analogues of 1, which replaced the cyanophenyl group with various biaryls, led to the discovery of highly potent dual FPTase/GGPTase-I inhibitors. 4-Trifluoromethylphenyl, trifluoropentynyl, and trifluoropentyl were identified as good p-cyano replacements.
- Nguyen, Diem N.,Stump, Craig A.,Walsh, Eileen S.,Fernandes, Christine,Davide, Joseph P.,Ellis-Hutchings, Michelle,Robinson, Ronald G.,Williams, Theresa M.,Lobell, Robert B.,Huber, Hans E.,Buser, Carolyn A.
-
p. 1269 - 1273
(2007/10/03)
-
- Inhibitors of prenyl-protein transferase
-
The present invention is directed to compounds which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting a prenyl-protein transferase and the prenylation of the oncogene protein Ras.
- -
-
-
- Diaryl ether inhibitors of farnesyl-protein transferase
-
Imidazolemethyl diaryl ethers are potent inhibitors of farnesyl-protein transferase. The SNAr displacement reaction used to prepare these diaryl ethers was amenable to rapid parallel synthesis of FPTase inhibitors. The use of a broad range of c
- MacTough, Suzanne C.,Desolms, S. Jane,Shaw, Anthony W.,Abrams, Marc T.,Ciccarone, Terrence M.,Davide, Joseph P.,Hamilton, Kelly A.,Hutchinson, John H.,Koblan, Kenneth S.,Kohl, Nancy E.,Lobell, Robert B.,Robinson, Ronald G.,Graham, Samuel L.
-
p. 1257 - 1260
(2007/10/03)
-
- Heterocyclic amide compounds and medicinal uses thereof
-
PCT No. PCT/JP97/03839 Sec. 371 Date Apr. 22, 1999 Sec. 102(e) Date Apr. 22, 1999 PCT Filed Oct. 22, 1997 PCT Pub. No. WO98/18794 PCT Pub. Date May 7, 1998A heterocyclic amide compound of the formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and a pharmaceutical use thereof. The heterocyclic amide compound and a pharmacologically acceptable salt thereof of the present invention have superior inhibitory action on chymase group in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be used for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.
- -
-
-
- INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
- -
-
-
- Hydrophobic benzoic acids as inhibitors of influenza neuraminidase
-
Neuraminidase (NA) plays a critical role in the life cycle of influenza virus and is a target for new therapeutic agents. A new benzoic acid inhibitor (11) containing a lipophilic side chain at C-3 and a guanidine at C-5 was synthesized. The X-ray structu
- Atigadda, Venkatram R.,Brouillette, Wayne J.,Duarte, Franco,Babu, Yarlagadda S.,Bantia, Shanta,Chand, Pooran,Chu, Naiming,Montgomery, John A.,Walsh, David A.,Sudbeck, Elise,Finley, James,Air, Gillian M.,Luo, Ming,Laver, Graeme W.
-
p. 2487 - 2497
(2007/10/03)
-
- Methotrexate derivative
-
Disclosed is a compound represented by the formula: STR1 wherein R1 : CH2, CH2 CH2, CH2 O, CH2 S, CH2 SO; R2 : hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms or a benzyl group; n: an integer of 1 to 4; R3 : COOR4, NHCOR5, CONR6 R7, PO3 H2, SO3 H. The compound shows potent antirheumatic function, psoriasis curing function and carcinostatic function and has low toxicity whereby it is available as a medicine.
- -
-
-
- SEMI-SYNTHESIS OF A.23187 (CALCIMYCIN) ANALOGS WITH 5-N-AMINO SUBSTITUENTS. THEIR COMPLEXATION OF CALCIUM AND MAGNESIUM
-
The semi-synthesis of A.23187 (calcimycin) analogs 1-4 bearing the respective substituents: 5-NH2, 5-NHCH3, 5-N(CH3)2, 5-NHCOCH3 was carried out.The complexing properties of 1-4 for calcium and magnesium were determined by two-phase experiments (water/toluene-butanol 70:30 W:W) and found to be much weaker than these of A.23187 or X.14885A.There was a discrepancy with theoretical predictions made from model carboxybenzoxazoles.
- Samih, Fouzia,Prudhomme, Michelle,Dauphin, Gerard,Jeminet, Georges
-
p. 5177 - 5186
(2007/10/02)
-
- Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions
-
Aromatic heterocyclic derivatives have the formula STR1 wherein R1 represents STR2 wherein R3 represents hydrogen, --OR4 wherein R4 represents hydrogen, alkyl having 1-20 carbon atoms or mono- or polyhydroxyalkyl or R3 represents STR3 wherein r' and r" represent hydrogen, lower alkyl or together form a heterocycle, R2 represents hydrogen or --CH3 and Ar represents STR4 wherein Z is O or S, STR5 wherein R5 is lower alkyl or STR6 wherein R6 is hydrogen or alkyl having 1-10 carbon atoms and R7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH or a nitrogen atom and X represents oxygen, sulfur or --N--R8 when R8 represents hydrogen, lower alkyl or lower alkoxycarbonyl, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C and (ii) when Y is nitrogen and X is oxygen, Ar is other than (C) or (D) in which R6 is alkyl having 1-4 carbon atoms and R7 is branched alkyl having 4-12 atoms useful in veterinary or human therapy and in cosmetic formulations.
- -
-
-